Spike protein and components (S1 subunit) found 15 months in the blood after infection, suggestive of same for those vaccinated; can be catastrophic and was NOT studied by Pfizer or imposed by FDA

we do not know what the long term impact of prolonged spike in the blood stream and at this rate, with multiple shots and boosting, we will NEVER clear spike out of the blood stream

Chronic COVID-19 symptoms (long COVID or Post-Acute Sequelae of COVID-19 (PASC)) have emerged in as many as 30% of infected persons. Researchers continue to search for the etiology but it is widely accepted that there are residual symptoms post COVID. Patterson et al. sought to examine the presence of SARS-CoV-2 S1 subunit protein in 46 persons and analyzed T-cell, B-cell, and monocytic subsets in both severe COVID-19 patients and in patients with post-acute sequelae of COVID-19 (PASC). Patterson’s findings raise many alarm bells. Severe acute respiratory syndrome coronavirus 2 binds to cells via the S1 subunit of its spike protein. Patterson et al. found that “the levels of both intermediate (CD14+, CD16+) and non-classical monocyte (CD14Lo, CD16+) were significantly elevated in PASC patients up to 15 months post-acute infection compared to healthy controls (P=0.002 and P=0.01, respectively). A statistically significant number of non-classical monocytes contained SARS-CoV-2 S1 protein in both severe (P=0.004) and PASC patients (P=0.02) out to 15 months post-infection.” 

What does this mean? It means that if each injection that introduces spike will result in spike and components remaining in the blood for 15 months, then by that timeline, it will take many years to clear spike out of the blood stream. How would the body or does the body react to this? Was our immune system set up for this?

What does this mean? It means by this timeline that we will never be able to clear spike or its components out of the circulation, and only after many, many years if the 15 months clock begins after each shot. It means if we are willing to infer, that the presence of non-classical monocytes containing SARS-CoV-2 S1 protein (S1 subunit) in both severe and PASC patients at 15 months post infection, could be mirrored by the presence of SARS-CoV-2 S1 protein (S1 subunit) or similar 15 months post COVID vaccination. This is very troubling and raises a host of safety questions given we do not know the implications. Moreover, those in opposition to this hypothesis are limited in any argument to our hypothesis given the vaccine developers failed to study this over the proper duration of follow-up and the FDA failed in their regulatory role to enforce this being studied. Similar to how the FDA failed to ensure ADE was studied or the implications of multiple boosting or the impact of the COVID vaccine on children long term e.g. on the innate immunity of children that typically functions to protect children against SARS-CoV-2 and a range of other pathogen. We just do not know the implications of spike and its components entering the blood stream and where it goes and for how long and exactly what it does, because the vaccine developers Pfizer et al. failed to conducted the proper study.

An important piece to the puzzle emerged from a request to the Japanese regulatory agency. Based on this confidential report (PHARMACOKINETICS: ORGAN DISTRIBUTION CONTINUED pages 6 & 7), we uncovered information of the bio-distribution in animals that shows that the vaccine content and lipid nano-particles (and thus potentially the spike protein) does not stay in the shoulder muscle and this finding is very potentially catastrophic. Why? Because the report indicates that the vaccine content (and thus by extension the translated spike protein) gets into the blood stream and could circulate in the blood systemically and accumulate in tissues such as the spleen, bone marrow, liver, adrenal glands, and ovaries. This is seen in the animal model and what we speculated on is now borne out by this data. The bio-distribution alarmingly shows that and suggests then that the spike proteins in humans may not stay in the injection site and may indeed travel throughout the body. This is a major concern and can explain the harms and severe outcomes we are seeing post vaccination.

Ogata et al. put additional pieces to the puzzle (on whether the spike protein or components are found long-term in the circulation) in their study of circulating SARS-CoV-2 vaccine antigen which was detected in the plasma of mRNA-1273 vaccine recipients. They collected plasma samples from 13 subjects (a prospective pilot study of 13 healthcare workers, 18 years and older, with no known history of SARS-CoV-2 infection conducted at the Brigham and Women’s Hospital from December 2020 to March 2021) who received two doses of mRNA-1273 vaccine and found that in 11 of the 13, there was detectable levels of SARS-CoV-2 protein one day (24 hours) post vaccination. Researchers found no antigen at day zero for 12 of 13 participants and “one individual presented detectable S1 on day zero, possibly due to assay cross-reactivity with other human coronaviruses or asymptomatic infection at the time of vaccination…for one individual (participant 8), spike was detected at day 29, 1 day after the second injection…after the second vaccine dose, no S1 or spike was detectable, and both antigens remained undetectable through day 56.”

Additional study was completed by Rhea et al. who found that the S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice. They reported that intravenously injected radio-iodinated S1 (I-S1) “readily crossed the blood-brain barrier in male mice, was taken up by brain regions and entered the parenchymal brain space. I-S1 was also taken up by the lung, spleen, kidney and liver. Intranasally administered I-S1 also entered the brain.”

Similarly, Bansal et al. studied the kinetics of induction of circulating exosomes with SARS-CoV-2 spike protein and Ab following vaccination of healthy individuals. Researchers reported “induction of circulating exosomes expressing spike protein on day 14 after vaccination followed by Abs 14 d after the second dose. Exosomes with spike protein, Abs to SARS-CoV-2 spike, and T cells secreting IFN-γ and TNF-α increased following the booster dose. Transmission electron microscopy of exosomes also demonstrated spike protein Ags on their surface. Exosomes with spike protein and Abs decreased in parallel after four months.” 

We are particularly concerned about spike protein and its components remaining in the circulation post vaccination (or any of the spike subunits S1 or S2 etc.) given additional troubling research findings. We are concerned about the behaviour of the spike protein within the circulation and as it interacts with the blood vessel walls (endothelium, glycocalyx, pericytes etc.) and the crossing of the blood-brain barrier. This remains a black-box as it was not studied nor mandated by the FDA.

In December 2020, Dr. J. Patrick Whelan, a pediatric rheumatologist, warned the FDA that mRNA vaccines could cause microvascular injury to the brain, heart, liver and kidneys in ways NOT assessed in safety trials. Whelan stated: “Is it possible the spike protein itself causes the tissue damage associated with Covid-19? Nuovo et al (in press) have shown that in 13/13 brains from patients with fatal COVID-19, pseudo-virions (spike, envelope, and membrane proteins) without viral RNA are present in the endothelia of cerebral micro-vessels.

Furthermore, tail vein injection of the full length S1 spike subunit in mice led to neurologic signs (increased thirst, stressed behavior) not evident in those injected with the S2 subunit. The S1 subunit localizes to the endothelia of micro-vessels in the mouse brain, and is a potent neurotoxin. So the spike S1 subunit of SARS-CoV-2 alone is capable of being endocytosed by ACE-2 positive endothelia in both human and mouse brain, with a concomitant pauci-cellular micro-encephalitis that may be the basis for the neurologic complications of COVID-19”. Whelan further states “it appears that the viral spike protein that is the target of the major SARS-CoV-2 vaccines is also one of the key agents causing the damage to distant organs that may include the brain, heart, lung, and kidney”. If this is so and validated, then we have to urgently assess the impact of these vaccines on the heart for this can be devastating if millions of vaccinated persons incur long-lasting permanent injury to their heart vasculature or brain. Whelan argues it would be terrible if we failed “to appreciate in the short-term an unintended effect of full-length spike protein-based vaccines on these other organs”.

Suresh (2020) reported that “in addition to facilitating the membrane fusion and viral entry, the SARS-CoV-2 spike protein promotes cell growth signaling in human lung vascular cells, and patients who have died of COVID-19 have thickened pulmonary vascular walls, linking the spike protein to a fatal disease, pulmonary arterial hypertension (PAH)”.

Suzuki (2021) examined SARS-CoV-2 Spike protein’s capacity to elicit cell signaling in human host cells and the implications for possible consequences of COVID-19 vaccines. They cautioned that while the aim is for the vaccines to para “introduce the spike protein into our body to elicit virus-neutralizing antibodies…we note that human host cells sensitively respond to the spike protein to elicit cell signaling…it is important to be aware that the spike protein produced by the new COVID-19 vaccines may also affect the host cells”. 

Zhang (2020) examined SARS-CoV-2 binding to platelet ACE 2 and the role in enhancing thrombosis (blood clotting) in COVID-19. They used platelets from healthy volunteers, non-COVID-19 and COVID-19 patients, including wild-type and hACE2 transgenic mice. They reported a different function of SARS-CoV-2 “on platelet activation via binding of Spike to ACE 2”. They reported that SARS-CoV-2-induced platelet activation “may participate in thrombus formation and inflammatory responses in COVID-19 patients”.

Similarly, Lei et. al. (2021) also reported that pseudo-virus contributed to inflammation and damage in both the arteries and lungs of mice exposed intratracheally. They “exposed healthy human endothelial cells to the same pseudo-virus particles. Binding of these particles to endothelial ACE 2 receptors led to mitochondrial damage and fragmentation in those endothelial cells, leading to the characteristic pathological changes in the associated tissue”. This research raised the very serious prospect that the spike protein on its very own, without the rest of the virus and the genome, can cause endothelial damage “associated with COVID-19”.

What does all of this mean? What happens if these reports and the evidence we have presented above proves true and the spike protein does behave pathogenically, as we believe it does? Then we have made a catastrophic mistake with the spike protein as the key antigen for our immune system to target. We have set up persons who have been vaccinated for possible harms and we cannot ‘exclude harms’ because it was not studied. The belief by those who developed the vaccine that the spike was an optimal target for the immune system was very flawed if this proves true and we now know that the spike may be possibly functioning as a toxin and pathogen, potentially capable of long-term disaster. The safety of the COVD-19 vaccines are in question. These narrow ‘spike-specific’ conferred immunity vaccines are in no way more optimal than broad, robust, durable immunity gained from natural exposure. Vaccine immunity does not supersede the potent innate immunity that we have and children come with that is so very effective (and often disregarded). We know that immunity can be lifelong.